Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 32 for “"HER2-positive"”.
-
Metabolic vulnerability in HER2-positive Breast Cancer
… human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… and human epidermal growth factor receptor 2 (HER2). Historically, HER2-positive breast cancers had a worse survival prognosis than oestrogen or progesterone receptor-positive cancers, but the development of HER2-targeted therapies led to significant survival improvements. Despite this, …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… rates. Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of BC. HER2 overexpression is also observed in other cancers such as gastric/gastroesophageal, ovarian, lung, prostate, bladder, colon and head and neck. HER2-positive BC is characterized by aggressive disease and …
-
Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer
<p>HER2-positive breast cancer, which is characterized by the over-expression of the HER2 onco-protein, accounts for approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling …
-
NF1 AS A REGULATOR OF CYTOSKELETON DYNAMICS AND BIOMARKER FOR DECISION-MAKING IN HER2-POSITIVE BREAST CANCER
… mutated gene between metastatic and primary HER2+ breast cancer (BC), so we investigated the biological consequences of NF1 loss on sensitivity to antineoplastic treatment and on the metastatic process. We generated NF1 knockout (KO) HER2+ BC cells (i.e.: BT-474, SK-BR-3, HCC1954) by …
-
A NOVEL, RAS-INDEPENDENT ROLE FOR NF1 IN MICROTUBULE DYNAMICS AND DAMAGE REPAIR DICTATES SENSITIVITY TO T-DM1 IN HER2 POSITIVE BREAST CANCER.
… in resistance to both endocrine and anti-HER2 agents. This has been attributed to the best characterized activity of NF1, its GTPase-activating protein (GAP) function that attenuates RAS signaling. NF1 encodes Neurofibromin (NF1), a large multifunctional protein consisting of 2,818 amino …
-
Comprehensive gene assessment of estrogen receptor positive breast cancers reveals that HER2 positive status plays an important role in resistance to neoadjuvant letrozole
Background The ER positive/ HER2 positive molecular subtype accounts for up to 10% of all breast cancers, these cancers have a worse prognosis than ER positive/ HER2 negative breast cancers. There is considerable evidence that ER positive/ HER2+ positive cancers exhibit resistance to endocrine …
-
Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer
… Deruxtecan, T-DXd, Enhertu) σε ασθενείς με HER2-θετικό καρκίνο του μαστού, εστιάζοντας στην αποτελεσματικότητα, την ασφάλεια και τον ρόλο της στα σύγχρονα θεραπευτικά σχήματα. Μεθοδολογία: Πραγματοποιήθηκε συστηματική αναζήτηση στη βιβλιογραφία σε βάσεις δεδομένων όπως PubMed, Scopus και …
-
Pathological response of breast cancer to neo-adjuvant chemotherapy at a single tertiary centre with no access to Trastuzumab
… and Trastuzumab for individuals with HER2-positive breast cancer, Groote Schuur Hospital faces constraints in administering Trastuzumab due to cost-related considerations. This study delves into the impact of neoadjuvant chemotherapy on breast cancer patients, specifically focusing on …
-
The perioperative setting as a platform for breast cancer biomarker development
… II-III human epidermal growth factor receptor-2 (HER2) positive breast cancer. The identification of predictive biomarkers of response to systemic therapy is of great research interest, as this may allow treatment to be tailored to the individual. Pathologic complete response (pCR), the absence of …
-
Identification of substrate-selective histone deacetylases and their inhibitors that mediate HER2 transcript stability
… women. 15-20% of these cancers overexpress the HER2 (ERRB2) oncoprotein. HER2-positive breast cancers are generally aggressive and are associated with poor prognosis. Unfortunately, only a mere 30% of HER2-positve patients respond to therapies when they are used as a single agent. Combining …
-
Identification of Markers to Predict Benefit from Trastuzumab Treatment
… Whole-transcriptome analysis of primary HER2-positive breast carcinomas (BCs) treated with adjuvant trastuzumab identified a tumour subgroup, characterised by high <i>ERBB2</i>/low <i>ESR1</i> expression, with good clinical outcome, and allowed the development of a trastuzumab risk model …
-
Rational design, characterization and in vivo studies of antibody mimics against HER2
<p>Human Epidermal Growth Factor Receptor 2 (HER2) is a cell surface receptor tyrosine kinase and plays a role in the signal pathways leading to cell proliferation and differentiation. Overexpression of HER2 is found in various cancers including breast, ovarian, gastric, colon, and non-small-cell …
-
An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
… hypothesis is that delineation of the effects of HER2-targeted therapy with the tyrosine kinase inhibitor (TKI) lapatinib, in vitro, and elucidation of the ensuing conformational changes may help understand the molecular activity of lapatinib and elucidate mechanisms of resistance. Clinical …
-
Identification and Characterization of Her2/Neu-Transformed Breast Cancer Stem Cells
… stem cells in our model system that mimics Her2-positive subtype of human breast cancer, we cultivated primary tumor cells and grew tumorspheres under non-adherent condition. Cells capable of forming tumorspheres retained ability of self-renewal and capacity for initiating tumors that …
-
Exploring the mechanism of SHP2 and EGFR/HER2 cooperation in breast cancer cell signaling
… of receptor tyrosine kinases like EGFR and HER2. As such, targeting of SHP2 is being recognized as a potentially viable therapeutic option in HER2-positive and triple-negative breast cancers. In this report, I employed molecular and cellular biology techniques to further elucidate the role …
-
Estradiol Regulation of Leucine-Rich Repeat Immunoglobulinlike Domains Protein 1 (Lrig 1) and Roles of Estrogen Receptor in Translational Regulation in Breast Cancer Cells
… as colony formation and invasiveness of ERalpha-positive and HER2-positive BT-474 and ERalpha-positive and HER2-negative MCF-7 breast cancer cell lines. LRIG1 regulation by estradiol may be important for breast cancer etiology and phenotypic properties by influencing signaling pathways such as …
-
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
… and trastuzumab emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive biomarkers for ADCs, …
-
Novel Paclitaxel Nanoparticles for Enhanced Therapeutic Effects in Breast Cancer
… (PR) and human epidermal growth factor receptor (HER2), there is no specific prognostic marker for targeting this aggressive cancer. In spite of rapid advancement in breast cancer with agents such as Trastuzumab in HER2 positive, chemotherapy with cytotoxic agents remains the mainstay treatment …
-
Azobenzenes for the development of therapeutics
… motif, bearing a cytotoxic payload, into an anti-HER2 trastuzumab antibody afforded a novel GSH-cleavable ADC that demonstrated selectivity towards HER2-positive cell lines, with a wide therapeutic window.
Page 1 of 2